BioNTech Overview

  • Founded
  • 2008
Founded
  • Status
  • Public
  • Employees
  • 1,941
Employees
  • Stock Symbol
  • BNTX
Stock Symbol
  • Investments
  • 15
  • Share Price
  • $126.25
  • (As of Monday Closing)

BioNTech General Information

Description

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.

Contact Information

Website
www.biontech.de
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • An der Goldgrube 12
  • 55131 Mainz
  • Germany
+49 06131 00000

BioNTech Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

BioNTech Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$126.25 $136.26 $90.29 - $464.00 $33B 243M 2.39M $36.83

BioNTech Financials Summary

In Thousands,
USD 		TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 65,421,540 18,809,932 7,267,406
Revenue 16,478,013 549,808 121,559 150,547
EBITDA 12,667,480 (121,536) (162,999) (30,626)
Net Income 8,954,052 17,324 (200,443) (56,666)
Total Assets 16,508,456 2,851,826 893,502 746,953
Total Debt 332,545 11,244 5,945 71,476
Public Fundamental Data provided by Morningstar, Inc. disclaimer

BioNTech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore BioNTech‘s full profile, request access.

Request a free trial

BioNTech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualiz
Biotechnology
Mainz, Germany
1,941 As of 2020
00.000
00000000 00.000

000000 0

incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ulla
0000000000000
Plymouth Meeting, PA
000 As of 0000
000.00
00000000 000.00

00000000

e magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip e
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BioNTech Competitors (43)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA 000 000.00 00000000 000.00
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000 Venture Capital-Backed Utrecht, Netherlands 00 00.000 0000000000 0 00.000
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
0000 0000 00000000 Formerly VC-backed Cambridge, MA 000 00000 00000000000 00000
You’re viewing 5 of 43 competitors. Get the full list »

BioNTech Patents

  • 996

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 72

    Granted

  • 39

    Pending

  • 000

    Expiring in next 12 mo

BioNTech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210338580-A1 Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell Pending 25-May-2021 0000000000
GB-202105465-D0 Coronavirus vaccine Pending 22-Apr-2020 0000000000
GB-202105481-D0 Coronavirus vaccine Pending 22-Apr-2020 0000000000
EP-3901261-A4 Coronavirus vaccine Pending 22-Apr-2020 000000000
EP-3901260-A4 Coronavirus vaccine Pending 22-Apr-2020 C12N15/11
To view BioNTech’s complete patent history, request access »

BioNTech Executive Team (18)

Name Title Board Seat Contact Info
Ugur Sahin MD Co-Founder and Chief Executive Officer
Sierk Poetting Ph.D Chief Operating Officer
Ryan Richardson Chief Strategy Officer, Strategy
Sean Marett Chief Business Officer & Chief Commercial Officer
Christopher Huber MD Co-Founder & Deputy Chair Supervisory Board
You’re viewing 5 of 18 executive team members. Get the full list »

BioNTech Board Members (2)

Name Representing Role Since
Helmut Jeggle Self Chairman & Board Member 000 0000
Michael Motschmann MIG AG Board Member 000 0000
To view BioNTech’s complete board members history, request access »

BioNTech Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioNTech Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore BioNTech‘s full profile, request access.

Request a free trial

BioNTech Investments & Acquisitions (15)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 25-Jan-2022 00000 0000 00000 Business/Productivity Software
00000000 0000 01-Oct-2021 0000000000 Biotechnology
0000 000000 ( 04-Aug-2021 000000000 Buildings and Property 0000 0000
00000 0000000 09-May-2021 00000 0000 Pharmaceuticals 0000 0000
AI Innovation Lab 25-Nov-2020 Joint Venture Drug Discovery 0000 0000
You’re viewing 5 of 15 investments and acquisitions. Get the full list »